Precision Medicine in Oncology

Mobocertinib Approved in EGFR Exon 20 Insertion+ NSCLC

September 15th 2021, 11:38pm


Patients with EGFR Exon20 insertion+ non–small cell lung cancer (NSCLC) make up approximately 1% to 2% of patients with NSCLC and have lacked treatment options.

MRD May Be Useful for Guiding Treatment Decisions in Multiple Myeloma

September 11th 2021, 6:00pm


According to researchers, new findings may have important implications for expanding the use of measurable residual disease (MRD) in multiple myeloma.

German Study Shows Savings Using ClonoSEQ to Guide Multiple Myeloma Treatment

September 10th 2021, 3:00pm


Study authors found that knowing a patient’s minimal residual disease status can help pinpoint the right multiple myeloma therapy to improve overall and progression-free survival.

A Review of Methods Being Investigated to Monitor MRD in MM

September 4th 2021, 4:15pm


A review looks at techniques to monitor minimal residual disease (MRD) in patients with multiple myeloma (MM).

Describing Sensitivity of ddPCR in Philadelphia-Positive ALL

September 2nd 2021, 6:45pm


The study, using a BCR/ABL1 assay, found that the novel method is able to detect minimal residual disease (MRD) in a larger range of patients compared with quantitative real‐time polymerase chain reaction, the method currently used to detect MRD.

Study Finds Contrasting Genomic Profiles Among Tissue Samples, Liquid Biopsies of Prostate Cancer

August 25th 2021, 10:30pm


The genomic alterations in prostate cancer were detected from tissue biopsies of primary tumors and metastatic sites as well as from liquid biopsies of circulating tumor DNA, the latter of which has emerged as an increasingly popular method for genomic analyses across various types of cancer.

ctDNA Successfully Detects Mutations With Treatment Implications in mCRC

August 23rd 2021, 1:30pm


Circulating tumor DNA (ctDNA) is a noninvasive way to identify mutations that may impact treatment decisions, according to a study of patients with metastatic colorectal cancer (mCRC).

Genomic Testing Creates Opportunities for Collaboration Between Academic Centers, Private Sector

August 16th 2021, 12:19pm


Precision Oncology Briefs: Cutting Breast Cancer Deaths; Enfortumab Vedotin; Rare CRC Mutations

August 14th 2021, 8:30pm


A meta-analysis showed adding trastuzumab to chemotherapy for the treatment of early-stage, HER2-positive breast cancer could cut deaths worldwide; a researcher discusses the promise of enfortumab vedotin for advanced urothelial cancers; more research is needed in rare genomic alterations in subsets of colorectal cancer (CRC).

NGS in Clinical Workflows Can Address Uterine Cancer Disparities, Study Finds

August 11th 2021, 6:45pm


Using next-generation sequencing (NGS) in clinical workflows may help address disparities in uterine cancer, which has a higher mortality for Black women.